Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

Number 5: The FDA has approved Imuldosa (ustekinumab-srlf), a biosimilar referencing Stelara (ustekinumab), for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...

During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona ...

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according ...

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while ...

A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...